Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
[forminator_form id="25163"]

afp.com.afp.com+1.who.int.Two experimental vaccines designed for the Bundibugyo strain of Ebola will begin testing in the Democratic Republic of Congo next week, the World Health Organization said on Tuesday, November 17. The DRC's worst Ebola outbreak on record has now passed 11,000 cases. "We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week," WHO chief Tedros Adhanom Ghebreyesus told reporters in Geneva, AFP reported.afp.com
The candidates are the University of Oxford's ChAdOx1 adenoviral vector vaccine and mRNA-1469 from Moderna . Both have finished smaller Phase 1 studies and will join the Tumaini trial, which has been running in Bunia, the capital of Ituri province, according to AFP. No vaccine or treatment is currently approved for Bundibugyo virus.afp.com
Meg Doherty, who heads WHO's science for health department, said both candidates were approved last week to move into Phase 2, and testing is expected to start on November 26 or 27 in Bunia, Anadolu Agency reported. Phase 2 will look at safety and immune response. Candidates that meet the criteria will go on to Phase 3, where their effectiveness will be measured against a comparator. Oxford developed ChAdOx1 together with the Serum Institute of India.mobil.aa.com.tr
Moderna said on November 4 that a WHO advisory group had recommended mRNA-1469 for the Phase 2/3 Tumaini study, subject to regulatory approval, according to the company's announcement. Tumaini is a randomized, blinded adaptive platform trial that uses ring vaccination, which means immunizing the contacts of confirmed cases. A separate Moderna Phase 1 study is testing mRNA-1469 in healthy adults at three sites in Canada.moderna2022rd.q4web.com
Tumaini started on October 23 with Ervebo, which is approved against the Zaire strain, to see whether it also protects against Bundibugyo, AFP noted. Ervebo is made by Merck & Co , according to the South China Morning Post. More than 140 people have enrolled so far, and thousands are expected as the trial adds sites and mobile teams, Doherty said.scmp.com+2
In opening remarks to WHO's emergency committee, Tedros said cases had more than doubled in three months, to over 11,000 cases and 5,400 deaths across 67 health zones in eight provinces. Between 400 and 500 new cases are still reported each week. AFP, citing WHO, gave a total of 11,376 confirmed cases and 5,568 deaths.who.int+1
Tedros said two-thirds of confirmed deaths are happening outside treatment centres, which suggests infections are being found too late. Children make up more than a quarter of confirmed cases and a third of deaths, he said, and seven in ten confirmed cases among children under five have been fatal. He described insecurity as "one of the greatest obstacles to the response."
He also warned against relying on the new shots alone. "Vaccines are not a substitute for the measures that save lives now," he said, listing early care, contact tracing, isolation, safe burials and trusted engagement with communities.